| Identification | Back Directory | [Name]
CT 112 | [CAS]
79714-31-1 | [Synonyms]
Risarestat
RISARESTAT (CT-112)
CT 112 (reductase inhibitor)
5-(3-Ethoxy-4-pentoxyphenyl)thiazolidine-2,4-dione
5-(3-Ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione
5-[3-Ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione
2,4-Thiazolidinedione, 5-[3-ethoxy-4-(pentyloxy)phenyl]- | [Molecular Formula]
C16H21NO4S | [MDL Number]
MFCD01940023 | [MOL File]
79714-31-1.mol | [Molecular Weight]
323.41 |
| Chemical Properties | Back Directory | [Boiling point ]
485.9±45.0 °C(Predicted) | [density ]
1.189±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
5.91±0.50(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications. | [Definition]
ChEBI: Risarestat is a thiazolidinone. | [in vivo]
Risarestat inhibits the accumulation of dulcitol in a dose-dependent manner, except for the 1.0% solution which has an activity comparable to the 0.25% solution[1]. Risarestat peaks in the corneal epithelium, stroma, endothelium and aqueous humor in 30 minutes following instillation, then gradually diminishes time-dependently over a period of 24 hours. Risarestat remains detectable in the lens up to 24 hours, with a peak concentration at 2 hours after instillation[2]. The anterior surface area of superficial cells in the group treated with Risarestat is significantly decreases from a mean value of 881 to 728 microns2. Corneal sensitivity significantly improves from 5.36 to 1.37 g/mm2[3]. Animals treated with Risarestat shows a significant increase in the mean blinkresponse compared to untreated galactose-fed rats and does not differ significantly from controls towards the completion of the 7 month study. Animals treated topically with Risarestat and untreated galactose-fed rats develop bilateral nuclear cataracts within 3 weeks[4]. | [References]
[1] Awata T, et al. Effect of an aldose reductase inhibitor, CT-112, on healing of the corneal epithelium in galactose-fed rats. J Ocul Pharmacol. 1988 Fall;4(3):195-201. DOI:10.1089/jop.1988.4.195
[2] Ohashi Y, et al. Intraocular penetration of CT-112, an aldose reductase inhibitor, following topical instillation. J Ocul Pharmacol. 1989 Winter;5(4):325-8. DOI:10.1089/jop.1989.5.325
[3] Hosotani H, et al. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol. 1995 Mar;119(3):288-94. DOI:10.1016/s0002-9394(14)71169-9
[4] Jacot JL, et al. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors. J Ocul Pharmacol Ther. 1998 Apr;14(2):169-80. DOI:10.1089/jop.1998.14.169 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|